Ebola vaccines show lasting effect

October 30, 2018

(HealthDay)—Three experimental Ebola vaccines trigger an immune response that lasts for more than two years against the deadly disease, researchers report.

In addition to being welcome news for the Ebola outbreak that's now spreading throughout the Democratic Republic of Congo, this success story is spurring research into the development of similar vaccines for other , the researchers added.

In the new study, British scientists analyzed blood samples taken from healthy volunteers who had received one of the three Ebola vaccine regimens more than two years earlier.

The results showed that all three vaccines "were still producing a strong antibody response to the two-and-a-half years after immunization, which is really good news," said study co-author Katie Ewer, from Oxford University in the United Kingdom.

The study was presented Monday at the American Society of Tropical Medicine and Hygiene's annual meeting, in New Orleans.

One of the vaccines is already being used to fight the outbreak in the Congo that aid workers are struggling to contain because it is unfolding in a highly dangerous conflict zone. With 155 deaths already confirmed since Ebola was declared in the country's northern region in August, fears of a cross-border epidemic are rising with new cases reported close to the Ugandan frontier, The Telegraph reported this week.

Meanwhile, the other two Ebola vaccines are being used as platforms for new vaccines against several other diseases with the potential to cause epidemics, including Lassa fever, Nipah virus disease, and Middle East respiratory syndrome coronavirus (MERS-CoV).

"The Ebola vaccine work that intensified after the in West Africa [2013-2016] has produced an explosion of vaccine development that could leave us much better prepared to fight other outbreaks of infectious diseases," Ewer said in a society news release.

"It has helped policy makers and funders understand the need. And that support has helped validate new vaccine platforms, including one that is adaptable for a number of viral diseases," Ewer explained.

Study co-author Dr. Matthew Snape, who's also from Oxford, said the findings "will be invaluable when deciding which strategy to use to induce long-lasting protection, for example in health care workers in areas at ongoing risk of Ebola outbreaks."

Snape added that "another important question is whether the persistence of this can be enhanced by giving a 'late-booster' dose of 3 to 4 years after the initial immunization, and we will be studying this in further work in the U.K. and Senegal in the coming year."

Research presented at meetings should be considered preliminary until published in a peer-reviewed journal.

Explore further: New evidence of durable immune response to 3 experimental Ebola vaccines helps drive new wave of vaccine development

More information: The U.S. Centers for Disease Control and Prevention has more on Ebola.

Related Stories

New evidence of durable immune response to 3 experimental Ebola vaccines helps drive new wave of vaccine development

October 30, 2018
In the midst of an increasingly volatile Ebola outbreak in the Democratic Republic of Congo, a new study presented today finds that the immune response generated by three experimental Ebola vaccines—including one already ...

WHO reports new Ebola case in DR Congo, vaccine this week

May 14, 2018
The head of the World Health Organization said Sunday there has been another reported case of Ebola in the Democratic Republic of Congo and that an experimental vaccine to fight the disease is expected to become available ...

In the fight against Ebola in the Congo, pregnant women must not be forgotten

August 31, 2018
The latest outbreak of Ebola in the Democratic Republic of Congo was declared on Aug. 1, with more than 100 confirmed and probable cases in eastern provinces. According to Congo's health ministry, more than 70 people have ...

Two Ebola patients who received experimental Tx have recovered

August 28, 2018
(HealthDay)—Two of the first 10 people to receive an experimental Ebola treatment have recovered from the highly dangerous disease, Congo's health ministry says.

Ebola vaccines provide immune responses after one year

March 14, 2017
Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.

Congo health ministry preps for possible Ebola vaccinations

August 6, 2018
Congo's health ministry is preparing to begin Ebola vaccinations Wednesday in the eastern city of Beni and neighboring Mangina village where the outbreak was announced last week, the ministry said.

Recommended for you

New inflammation inhibitor discovered

November 16, 2018
A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action. By inhibiting a certain protein, the researchers were able ...

Gut hormone and brown fat interact to tell the brain it's time to stop eating

November 15, 2018
Researchers from Germany and Finland have shown that so-called "brown fat" interacts with the gut hormone secretin in mice to relay nutritional signals about fullness to the brain during a meal. The study, appearing November ...

Brain, muscle cells found lurking in kidney organoids grown in lab

November 15, 2018
Scientists hoping to develop better treatments for kidney disease have turned their attention to growing clusters of kidney cells in the lab. One day, so-called organoids—grown from human stem cells—may help repair damaged ...

How the Tasmanian devil inspired researchers to create 'safe cell' therapies

November 15, 2018
A contagious facial cancer that has ravaged Tasmanian devils in southern Australia isn't the first place one would look to find the key to advancing cell therapies in humans.

Researchers discover important connection between cells in the liver

November 15, 2018
University of Minnesota Medical School researchers have made a discovery which could lead to a new way of thinking about how disease pathogenesis in the liver is regulated, which is important for understanding the condition ...

Precision neuroengineering enables reproduction of complex brain-like functions in vitro

November 14, 2018
One of the most important and surprising traits of the brain is its ability to dynamically reconfigure the connections to process and respond properly to stimuli. Researchers from Tohoku University (Sendai, Japan) and the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.